Sector News

Novo Nordisk enters deal to develop obesity therapy

May 11, 2024
Life sciences

Novo Nordisk has entered a research partnership with Flagship Pioneering and Metaphore Biotechnologies to jointly develop up to two next-generation therapeutics for the management of obesity.

The collaboration forms part of a strategic deal between Novo Nordisk and Flagship, focusing on new treatment approaches for cardiometabolic and rare diseases.

Pioneering Medicines, a division of Flagship responsible for drug development and partnerships, will lead the collaboration alongside Novo Nordisk’s Bio Innovation Hub.

The Bio Innovation Hub is a research and development (R&D) unit that expedites therapeutic development through co-creation collaborations.

Metaphore will collaborate with Pioneering Medicines and Novo Nordisk to progress the programmes from foundational activities to preclinical development.

The collaboration will utilise Metaphor’s MIMIC platform to create multitarget therapies that act on the GLP-1 receptor and related biology.

The goal is to develop scalable, long-acting agents that allow infrequent dosing.

Novo Nordisk may make upfront, development and commercial milestone payments of $600m, in addition to tiered royalty payments on annual net product sales.

These payments and royalties will be shared between Pioneering Medicines and Metaphore.

Novo Nordisk will reimburse R&D expenses and contribute to Metaphore’s future financing round.

Metaphore co-founder and CEO and Flagship Pioneering origination partner Lovisa Afzelius stated: “Working with Novo Nordisk is a significant opportunity to apply our MIMIC platform in one of the most exciting areas of drug development and with one of the most experienced drug development teams working in obesity.

“This collaboration could further validate our unique ability to programme function into therapeutic molecules with the MIMIC platform to enhance efficacy, extend durability and optimise manufacturing for a single therapeutic addressing multiple obesity-related targets, including but not limited to the GLP-1 receptor.”

Earlier this month, Novo Nordisk reported DKr61bn ($8.7bn) in sales from its diabetes and obesity portfolio, accounting for 93.3% of its total sales in Q1 2024.

Source: pharmaceutical-technology.com

comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach